of the Program Data in TARA-002's BLA filing, as set forth below: Official Feedback from FDA regarding the Program Data Milestone […***…] $[…***…] […***…] $[…***…] […***…] $[…***…] […***…] […***…] 5 Source: ARTARA THERAPEUTICS, INC., 8-K, 1/10/2020 3.3 Royalties. Royalties will be payable by ArTara on Net Sales of Product in the Indication. ArTara will, no later than […***…] following the close of each calendar quarter, pay tiered Royalties based on annual Net Sales of Product in the Indication as set forth below: Annual Net Sales of Product for the Indication Annual Royalty Rate Percent Net Sales $0 - $25,000,000 1.75% >$25,000,000 - $50,000,000 2.25% >$50,000,000 2.50% 3.4 Royalty Reduction. In the event the Regulatory Authorities determine that the Program Data is not sufficient for Regulatory Approvals on its own and additional pediatric efficacy and safety clinical studies are required, Royalties set forth above will be reduced by […***…] percent ([… ***…]%). 3.5 Sales Milestone Payments. In the event that Annual Net Sales, as detailed in Section 3.3, surpass certain thresholds, ArTara will make the following payments no later than […***…] following the close of the calendar quarter in which each milestone is reached as set forth below: Annual Net Sales of Product for the Indication Exceeds Milestone Payment $25,000,000 $62,500 $50,000,000 $62,500 $100,000,000 $125,000 3.6 Payments. All payments under Articles 3.2, 3.3 and 3.5 shall be sent to the following address: Checks will be sent to: The University of Iowa Research Foundation ATTN: Accounting 6 Gilmore Hall 112 North Capitol St. Iowa City, IA 52242-5500 Wire transfers will be sent to: […***…] 6 Source: ARTARA THERAPEUTICS, INC., 8-K, 1/10/2020 ArTara will include the University of Iowa Research Foundation agreement number 2019- 068, a reference to "Richard Smith, MD, ArTara Sponsored Research and License Agreement dated November 28, 2018" and purpose